Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $2.73B
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.08
• Revenue Growth: -84.07%
• EPS Growth: -157.71%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 101,474,945
• 10 Day Avg. Volume: 1,870,441
• 30 Day Avg. Volume: 1,676,695
• PEG Ratio: -0.03
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 32.14
• P/FCF Ratio: -5.73
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 42.96
• Enterprise Value/Gross Profit: -6.72
• Enterprise Value/Ebitda: -5.56
• 1Y Price Target: $48.56
• Price Target Upside: 80.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $28.00 ▲(3.90% Upside)

The score is held back primarily by weak financial performance (declining revenue, very large losses, and negative cash flows). Technicals are constructive with strong trend and positive MACD, but overbought RSI adds near-term risk. Corporate events are a meaningful positive (extended runway and regulatory/clinical progress), while valuation support is limited due to losses and a negative P/E.

Positive Factors

Extended cash runway

A reported cash balance near $1.25B and a stated runway into 2029 materially reduces near-term financing pressure and gives management time to complete pivotal studies and pursue regulatory filings. This liquidity supports execution of multi-year clinical programs and commercial preparations.

Regulatory alignment for BEAM-302

FDA alignment on an accelerated pathway and inclusion in the CMC pilot are durable positives: they can shorten timelines, reduce required clinical evidence relative to traditional approvals, and lower regulatory uncertainty for BEAM-302, increasing probability of a faster route to market if trials meet biomarker endpoints.

Platform and diversified pipeline

A multi-franchise pipeline across liver genetic diseases and hematology, plus platform work (in vivo editing, ESCAPE, LNPs), spreads development risk and creates multiple commercialization pathways. Platform scalability increases long-term optionality beyond any single asset's outcome.

Negative Factors

Declining revenue

Trailing revenue contraction signals that current collaboration/licensing income isn't providing growth stability. For a clinical-stage biotech, declining revenue undermines internal funding capacity and heightens dependence on external financing or milestone receipts to sustain multi-year R&D programs.

Very large losses

Extremely negative net margins reflect heavy R&D and operating spend without product revenue. Persistently large losses compress return on equity and create structural profitability risk, meaning long-term investor returns depend heavily on successful commercialization of pipeline assets.

Negative operating and free cash flow

Sustained negative operating and free cash flow, and steep FCF decline, indicate the company currently consumes cash to fund development. Even with an extended runway, continued cash burn creates persistent financing risk if timelines slip or milestones are delayed, limiting strategic flexibility.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Beam Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potential future product sales. The company partners with pharmaceutical companies and research institutions to co-develop its therapies, often receiving upfront payments, milestone payments as projects advance, and royalties on future sales. Additionally, Beam may monetize its proprietary technologies through licensing deals, allowing other companies to use their base editing technology in exchange for fees. As their product candidates advance through clinical trials and toward commercialization, potential sales of successful therapies will also contribute to revenue.

Beam Therapeutics Financial Statement Overview

Summary

Overall financial health is weak: revenue is declining (-7.58% TTM) with extremely negative profitability (net margin -901.34%) and negative operating/free cash flows. A relatively low debt-to-equity ratio (0.16) provides some balance-sheet support, but losses and cash flow pressure dominate.

Income Statement

Beam Therapeutics has experienced declining revenue and negative profit margins over the TTM period. The company shows a negative revenue growth rate of -7.58% and a significant net profit margin of -901.34%, indicating substantial losses. The EBIT and EBITDA margins are also deeply negative, reflecting operational challenges. Despite these issues, the company has shown some historical revenue growth, suggesting potential for future improvement.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.16, indicating a relatively low level of leverage. However, the return on equity is negative at -42.86%, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company maintains a reasonable level of stockholders' equity relative to its total assets, suggesting some financial stability despite profitability challenges.

Cash Flow

Beam Therapeutics has negative operating and free cash flows, with a free cash flow growth rate of -90.3% over the TTM period. The operating cash flow to net income ratio is -1.85, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive at 1.04, suggesting some ability to cover net losses with free cash flow, albeit limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	55.70M	63.52M	377.71M	60.92M	51.84M	24.00K
Gross Profit	-356.09M	-304.04M	377.71M	-250.67M	-180.29M	-103.16M
EBITDA	-430.13M	-393.64M	-146.95M	-324.33M	-230.06M	-128.03M
Net Income	-414.64M	-376.74M	-132.53M	-289.09M	-370.64M	-194.59M
Balance Sheet
Total Assets	1.31B	1.10B	1.46B	1.34B	1.47B	451.68M
Cash, Cash Equivalents and Short-Term Investments	1.07B	850.74M	1.19B	1.08B	965.65M	299.67M
Total Debt	151.42M	161.43M	172.69M	179.00M	147.64M	107.64M
Total Liabilities	345.08M	370.28M	478.38M	608.24M	647.72M	206.12M
Stockholders Equity	966.00M	733.54M	981.33M	733.47M	826.74M	245.56M
Cash Flow
Free Cash Flow	-352.36M	-356.19M	-182.93M	-26.42M	-113.08M	-112.10M
Operating Cash Flow	-338.18M	-347.25M	-149.19M	22.53M	-66.27M	-95.74M
Investing Cash Flow	-103.56M	185.01M	71.84M	-461.34M	-294.14M	-100.12M
Financing Cash Flow	479.61M	7.74M	276.45M	111.59M	756.14M	322.32M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 26.95
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Neutral. The current price of 26.95 is below the 20-day moving average (MA) of 30.48, below the 50-day MA of 28.12, and above the 200-day MA of 22.33, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 41.50 is Neutral, neither overbought nor oversold. The STOCH value of 10.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.19B	-73.54	-28.17%	―	129.21%	80.35%
IMVT	56 Neutral	$5.07B	-8.50	-95.93%	―	―	-27.70%
DNLI	54 Neutral	$3.32B	-6.88	-44.44%	―	―	-5.30%
BEAM	53 Neutral	$2.73B	-5.58	-47.19%	―	-84.07%	-157.71%
IRON	52 Neutral	$3.08B	-14.62	-34.78%	―	―	-34.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMCR	47 Neutral	$1.59B	-52.93	-7.52%	―	27.51%	38.72%

Beam Therapeutics Corporate Events

Beam Therapeutics outlines 2026 strategy and extends runway

On January 11, 2026, Beam Therapeutics outlined strategic priorities for 2026 across its genetic disease and hematology franchises, emphasizing progress in late-stage clinical programs and a substantially extended cash runway. The company reported clinical proof of concept for BEAM-302 in alpha-1 antitrypsin deficiency, treating more than 25 patients in an ongoing Phase 1/2 trial and securing U.S. FDA alignment on a potential accelerated approval pathway based on 12‑month biomarker endpoints, alongside inclusion of the program in the FDA’s CMC Development and Readiness Pilot. Beam is also advancing BEAM-301 for glycogen storage disease type Ia with a Phase 1/2 trial underway and initial data expected in 2026, and plans to disclose an additional liver-targeted program in the first half of 2026. In its hematology franchise, the company highlighted encouraging Phase 1/2 BEACON data for its sickle cell therapy risto-cel, which has fully enrolled adult and adolescent cohorts, completed manufacturing of all doses by December 2025, gained entry into the FDA’s CDRP program, and is being positioned for a biologics license application as early as year‑end 2026. Beam is simultaneously investing in next-generation in vivo gene-editing approaches for sickle cell disease, including targeted lipid nanoparticles for hematopoietic stem cell delivery and its ESCAPE platform, with a Phase 1 trial of the conditioning antibody BEAM‑103 expected to complete dosing in the first half of 2026. Financially, Beam estimated it ended 2025 with about $1.25 billion in cash, cash equivalents and marketable securities, supported in part by proceeds from Bristol-Myers Squibb’s acquisition of Orbital Therapeutics, and now projects its operating runway to extend into 2029, backing the anticipated commercial transition for risto-cel and pivotal development of BEAM‑302 and reinforcing its position as a well-capitalized emerging leader in genetic medicines.

The most recent analyst rating on (BEAM) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics Gains $255M from Orbital Acquisition

On December 8, 2025, Bristol-Myers Squibb completed its acquisition of Orbital Therapeutics, in which Beam Therapeutics held a 17% stake. Beam’s shares were converted into $255.1 million in cash, with potential for additional consideration, impacting its financial outlook ahead of the 2026 J.P. Morgan Healthcare Conference.

The most recent analyst rating on (BEAM) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.